Regeneron Sees FY24 Non-GAAP Gross Margin On Net Product Sales Approximately 89%, Unchanged From Prior
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has announced that its fiscal year 2024 non-GAAP gross margin on net product sales is expected to be approximately 89%, which remains unchanged from previous guidance.
October 31, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals has confirmed that its FY24 non-GAAP gross margin on net product sales will remain at approximately 89%, consistent with previous guidance.
The announcement that Regeneron's FY24 non-GAAP gross margin remains unchanged at 89% suggests stability in its financial outlook. This consistency may reassure investors, but it does not introduce new information that would significantly impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 100